Global In-Vitro Toxicity Testing Market

In-Vitro Toxicity Testing Comprehensive Study by Type (Absorption, Toxic Substances, Dose), Application (Systemic Toxicology, Dermal Toxicity, Endorine Disruption, Occular Toxicity, Others), Technology (Cell Culture Tech, High Throughput Tech, Molecular Imaging, OMICS Tech), Methods (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo), End User (Cosmetics and Household Products, Pharmaceutical Industry, Food Industry, Chemical Industry) Players and Region - Global Market Outlook to 2027

In-Vitro Toxicity Testing Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 15.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
In-Vitro Toxicity Testing Market Scope
In vitro is the method that helps observe harmful chemicals over the isolated part of the organism. It is used to recognize harmful chemical substances and helps identify the toxicity at the early stages of the development of new products such as drugs, cosmetics, and food additives. The in vitro toxicity testing is mainly used for safety evaluation in drug development. The absorption, distribution, metabolism, excretion (ADME), dose-response, threshold response of drug can also be determined by the in vitro toxicity testing.

According to AMA, the Global In-Vitro Toxicity Testing market is expected to see growth rate of 15.1%

Large size companies have focused on a new product launch to meet the specific requirements of the researchers. The companies are exploring the market in new regions by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. Key players are exploring new geographies through expansions and acquisitions across the globe to avail a competitive advantage through combined synergies Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global In-Vitro Toxicity Testing market throughout the predicted period.

Abbott (United States), Covance (United States), GE Healthcare (United States), Quest Diagnostics, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Bio-Rad Laboratories (United States), Catalent Pharma Solutions (United States), Cyprotex (Germany), Agilent Technologies (United States) and Charles River Laboratories (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Merck KgaA (Germany) and Eurofins Scientific, Inc. (Luxembourg).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global In-Vitro Toxicity Testing market by Type (Absorption, Toxic Substances and Dose), by Application (Systemic Toxicology, Dermal Toxicity, Endorine Disruption, Occular Toxicity and Others) and Region with country level break-up.

On the basis of geography, the market of In-Vitro Toxicity Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Advancement in Genetics and Genetic Screening Approaches
  • Emergence of New Approaches of 3D Cell Culture

Market Drivers
  • Upsurge in Number of R&D Procedures
  • Increase in Awareness about the Environmental Concerns

Opportunities
  • Government Has Also Taken Initiatives Including Opposition to Animal Testing Laws
  • Huge Demand in the Developing Countries

Restraints
  • Lack Of Predictive Ability and In Vitro Model

Challenges
  • Decrease in Adoption Rate of IVTT
  • Incapability of IVTT to Detect Toxicities Due To Autoimmunity and Immune Stimulation


Key Target Audience
Government Research Organization, Private Research Organization, Government Regulatory Bodies, Industry Association, Downstream Vendors and Others

Report Objectives / Segmentation Covered

By Type
  • Absorption
  • Toxic Substances
  • Dose
By Application
  • Systemic Toxicology
  • Dermal Toxicity
  • Endorine Disruption
  • Occular Toxicity
  • Others
By Technology
  • Cell Culture Tech
  • High Throughput Tech
  • Molecular Imaging
  • OMICS Tech

By Methods
  • Cellular Assay
  • Biochemical Assay
  • In Silica
  • Ex-vivo

By End User
  • Cosmetics and Household Products
  • Pharmaceutical Industry
  • Food Industry
  • Chemical Industry

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Upsurge in Number of R&D Procedures
      • 3.2.2. Increase in Awareness about the Environmental Concerns
    • 3.3. Market Challenges
      • 3.3.1. Decrease in Adoption Rate of IVTT
      • 3.3.2. Incapability of IVTT to Detect Toxicities Due To Autoimmunity and Immune Stimulation
    • 3.4. Market Trends
      • 3.4.1. Advancement in Genetics and Genetic Screening Approaches
      • 3.4.2. Emergence of New Approaches of 3D Cell Culture
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global In-Vitro Toxicity Testing, by Type, Application, Technology, Methods, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global In-Vitro Toxicity Testing (Value)
      • 5.2.1. Global In-Vitro Toxicity Testing by: Type (Value)
        • 5.2.1.1. Absorption
        • 5.2.1.2. Toxic Substances
        • 5.2.1.3. Dose
      • 5.2.2. Global In-Vitro Toxicity Testing by: Application (Value)
        • 5.2.2.1. Systemic Toxicology
        • 5.2.2.2. Dermal Toxicity
        • 5.2.2.3. Endorine Disruption
        • 5.2.2.4. Occular Toxicity
        • 5.2.2.5. Others
      • 5.2.3. Global In-Vitro Toxicity Testing by: Technology (Value)
        • 5.2.3.1. Cell Culture Tech
        • 5.2.3.2. High Throughput Tech
        • 5.2.3.3. Molecular Imaging
        • 5.2.3.4. OMICS Tech
      • 5.2.4. Global In-Vitro Toxicity Testing by: Methods (Value)
        • 5.2.4.1. Cellular Assay
        • 5.2.4.2. Biochemical Assay
        • 5.2.4.3. In Silica
        • 5.2.4.4. Ex-vivo
      • 5.2.5. Global In-Vitro Toxicity Testing by: End User (Value)
        • 5.2.5.1. Cosmetics and Household Products
        • 5.2.5.2. Pharmaceutical Industry
        • 5.2.5.3. Food Industry
        • 5.2.5.4. Chemical Industry
      • 5.2.6. Global In-Vitro Toxicity Testing Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global In-Vitro Toxicity Testing (Price)
      • 5.3.1. Global In-Vitro Toxicity Testing by: Type (Price)
  • 6. In-Vitro Toxicity Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Covance (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Quest Diagnostics, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Catalent Pharma Solutions (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cyprotex (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Agilent Technologies (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Charles River Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global In-Vitro Toxicity Testing Sale, by Type, Application, Technology, Methods, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global In-Vitro Toxicity Testing (Value)
      • 7.2.1. Global In-Vitro Toxicity Testing by: Type (Value)
        • 7.2.1.1. Absorption
        • 7.2.1.2. Toxic Substances
        • 7.2.1.3. Dose
      • 7.2.2. Global In-Vitro Toxicity Testing by: Application (Value)
        • 7.2.2.1. Systemic Toxicology
        • 7.2.2.2. Dermal Toxicity
        • 7.2.2.3. Endorine Disruption
        • 7.2.2.4. Occular Toxicity
        • 7.2.2.5. Others
      • 7.2.3. Global In-Vitro Toxicity Testing by: Technology (Value)
        • 7.2.3.1. Cell Culture Tech
        • 7.2.3.2. High Throughput Tech
        • 7.2.3.3. Molecular Imaging
        • 7.2.3.4. OMICS Tech
      • 7.2.4. Global In-Vitro Toxicity Testing by: Methods (Value)
        • 7.2.4.1. Cellular Assay
        • 7.2.4.2. Biochemical Assay
        • 7.2.4.3. In Silica
        • 7.2.4.4. Ex-vivo
      • 7.2.5. Global In-Vitro Toxicity Testing by: End User (Value)
        • 7.2.5.1. Cosmetics and Household Products
        • 7.2.5.2. Pharmaceutical Industry
        • 7.2.5.3. Food Industry
        • 7.2.5.4. Chemical Industry
      • 7.2.6. Global In-Vitro Toxicity Testing Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global In-Vitro Toxicity Testing (Price)
      • 7.3.1. Global In-Vitro Toxicity Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. In-Vitro Toxicity Testing: by Type(USD Million)
  • Table 2. In-Vitro Toxicity Testing Absorption , by Region USD Million (2016-2021)
  • Table 3. In-Vitro Toxicity Testing Toxic Substances , by Region USD Million (2016-2021)
  • Table 4. In-Vitro Toxicity Testing Dose , by Region USD Million (2016-2021)
  • Table 5. In-Vitro Toxicity Testing: by Application(USD Million)
  • Table 6. In-Vitro Toxicity Testing Systemic Toxicology , by Region USD Million (2016-2021)
  • Table 7. In-Vitro Toxicity Testing Dermal Toxicity , by Region USD Million (2016-2021)
  • Table 8. In-Vitro Toxicity Testing Endorine Disruption , by Region USD Million (2016-2021)
  • Table 9. In-Vitro Toxicity Testing Occular Toxicity , by Region USD Million (2016-2021)
  • Table 10. In-Vitro Toxicity Testing Others , by Region USD Million (2016-2021)
  • Table 11. In-Vitro Toxicity Testing: by Technology(USD Million)
  • Table 12. In-Vitro Toxicity Testing Cell Culture Tech , by Region USD Million (2016-2021)
  • Table 13. In-Vitro Toxicity Testing High Throughput Tech , by Region USD Million (2016-2021)
  • Table 14. In-Vitro Toxicity Testing Molecular Imaging , by Region USD Million (2016-2021)
  • Table 15. In-Vitro Toxicity Testing OMICS Tech , by Region USD Million (2016-2021)
  • Table 16. In-Vitro Toxicity Testing: by Methods(USD Million)
  • Table 17. In-Vitro Toxicity Testing Cellular Assay , by Region USD Million (2016-2021)
  • Table 18. In-Vitro Toxicity Testing Biochemical Assay , by Region USD Million (2016-2021)
  • Table 19. In-Vitro Toxicity Testing In Silica , by Region USD Million (2016-2021)
  • Table 20. In-Vitro Toxicity Testing Ex-vivo , by Region USD Million (2016-2021)
  • Table 21. In-Vitro Toxicity Testing: by End User(USD Million)
  • Table 22. In-Vitro Toxicity Testing Cosmetics and Household Products , by Region USD Million (2016-2021)
  • Table 23. In-Vitro Toxicity Testing Pharmaceutical Industry , by Region USD Million (2016-2021)
  • Table 24. In-Vitro Toxicity Testing Food Industry , by Region USD Million (2016-2021)
  • Table 25. In-Vitro Toxicity Testing Chemical Industry , by Region USD Million (2016-2021)
  • Table 26. South America In-Vitro Toxicity Testing, by Country USD Million (2016-2021)
  • Table 27. South America In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 28. South America In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 29. South America In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 30. South America In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 31. South America In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 32. Brazil In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 33. Brazil In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 34. Brazil In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 35. Brazil In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 36. Brazil In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 37. Argentina In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 38. Argentina In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 39. Argentina In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 40. Argentina In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 41. Argentina In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 42. Rest of South America In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 43. Rest of South America In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 44. Rest of South America In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 45. Rest of South America In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 46. Rest of South America In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 47. Asia Pacific In-Vitro Toxicity Testing, by Country USD Million (2016-2021)
  • Table 48. Asia Pacific In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 49. Asia Pacific In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 50. Asia Pacific In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 51. Asia Pacific In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 52. Asia Pacific In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 53. China In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 54. China In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 55. China In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 56. China In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 57. China In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 58. Japan In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 59. Japan In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 60. Japan In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 61. Japan In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 62. Japan In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 63. India In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 64. India In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 65. India In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 66. India In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 67. India In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 68. South Korea In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 69. South Korea In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 70. South Korea In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 71. South Korea In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 72. South Korea In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 73. Taiwan In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 74. Taiwan In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 75. Taiwan In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 76. Taiwan In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 77. Taiwan In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 78. Australia In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 79. Australia In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 80. Australia In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 81. Australia In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 82. Australia In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 83. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 84. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 85. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 86. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 87. Rest of Asia-Pacific In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 88. Europe In-Vitro Toxicity Testing, by Country USD Million (2016-2021)
  • Table 89. Europe In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 90. Europe In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 91. Europe In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 92. Europe In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 93. Europe In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 94. Germany In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 95. Germany In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 96. Germany In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 97. Germany In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 98. Germany In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 99. France In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 100. France In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 101. France In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 102. France In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 103. France In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 104. Italy In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 105. Italy In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 106. Italy In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 107. Italy In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 108. Italy In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 109. United Kingdom In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 110. United Kingdom In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 111. United Kingdom In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 112. United Kingdom In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 113. United Kingdom In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 114. Netherlands In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 115. Netherlands In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 116. Netherlands In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 117. Netherlands In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 118. Netherlands In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 119. Rest of Europe In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 120. Rest of Europe In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 121. Rest of Europe In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 122. Rest of Europe In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 123. Rest of Europe In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 124. MEA In-Vitro Toxicity Testing, by Country USD Million (2016-2021)
  • Table 125. MEA In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 126. MEA In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 127. MEA In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 128. MEA In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 129. MEA In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 130. Middle East In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 131. Middle East In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 132. Middle East In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 133. Middle East In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 134. Middle East In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 135. Africa In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 136. Africa In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 137. Africa In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 138. Africa In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 139. Africa In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 140. North America In-Vitro Toxicity Testing, by Country USD Million (2016-2021)
  • Table 141. North America In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 142. North America In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 143. North America In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 144. North America In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 145. North America In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 146. United States In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 147. United States In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 148. United States In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 149. United States In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 150. United States In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 151. Canada In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 152. Canada In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 153. Canada In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 154. Canada In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 155. Canada In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 156. Mexico In-Vitro Toxicity Testing, by Type USD Million (2016-2021)
  • Table 157. Mexico In-Vitro Toxicity Testing, by Application USD Million (2016-2021)
  • Table 158. Mexico In-Vitro Toxicity Testing, by Technology USD Million (2016-2021)
  • Table 159. Mexico In-Vitro Toxicity Testing, by Methods USD Million (2016-2021)
  • Table 160. Mexico In-Vitro Toxicity Testing, by End User USD Million (2016-2021)
  • Table 161. In-Vitro Toxicity Testing: by Type(USD/Units)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. In-Vitro Toxicity Testing: by Type(USD Million)
  • Table 173. In-Vitro Toxicity Testing Absorption , by Region USD Million (2022-2027)
  • Table 174. In-Vitro Toxicity Testing Toxic Substances , by Region USD Million (2022-2027)
  • Table 175. In-Vitro Toxicity Testing Dose , by Region USD Million (2022-2027)
  • Table 176. In-Vitro Toxicity Testing: by Application(USD Million)
  • Table 177. In-Vitro Toxicity Testing Systemic Toxicology , by Region USD Million (2022-2027)
  • Table 178. In-Vitro Toxicity Testing Dermal Toxicity , by Region USD Million (2022-2027)
  • Table 179. In-Vitro Toxicity Testing Endorine Disruption , by Region USD Million (2022-2027)
  • Table 180. In-Vitro Toxicity Testing Occular Toxicity , by Region USD Million (2022-2027)
  • Table 181. In-Vitro Toxicity Testing Others , by Region USD Million (2022-2027)
  • Table 182. In-Vitro Toxicity Testing: by Technology(USD Million)
  • Table 183. In-Vitro Toxicity Testing Cell Culture Tech , by Region USD Million (2022-2027)
  • Table 184. In-Vitro Toxicity Testing High Throughput Tech , by Region USD Million (2022-2027)
  • Table 185. In-Vitro Toxicity Testing Molecular Imaging , by Region USD Million (2022-2027)
  • Table 186. In-Vitro Toxicity Testing OMICS Tech , by Region USD Million (2022-2027)
  • Table 187. In-Vitro Toxicity Testing: by Methods(USD Million)
  • Table 188. In-Vitro Toxicity Testing Cellular Assay , by Region USD Million (2022-2027)
  • Table 189. In-Vitro Toxicity Testing Biochemical Assay , by Region USD Million (2022-2027)
  • Table 190. In-Vitro Toxicity Testing In Silica , by Region USD Million (2022-2027)
  • Table 191. In-Vitro Toxicity Testing Ex-vivo , by Region USD Million (2022-2027)
  • Table 192. In-Vitro Toxicity Testing: by End User(USD Million)
  • Table 193. In-Vitro Toxicity Testing Cosmetics and Household Products , by Region USD Million (2022-2027)
  • Table 194. In-Vitro Toxicity Testing Pharmaceutical Industry , by Region USD Million (2022-2027)
  • Table 195. In-Vitro Toxicity Testing Food Industry , by Region USD Million (2022-2027)
  • Table 196. In-Vitro Toxicity Testing Chemical Industry , by Region USD Million (2022-2027)
  • Table 197. South America In-Vitro Toxicity Testing, by Country USD Million (2022-2027)
  • Table 198. South America In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 199. South America In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 200. South America In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 201. South America In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 202. South America In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 203. Brazil In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 204. Brazil In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 205. Brazil In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 206. Brazil In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 207. Brazil In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 208. Argentina In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 209. Argentina In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 210. Argentina In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 211. Argentina In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 212. Argentina In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 213. Rest of South America In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 214. Rest of South America In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 215. Rest of South America In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 216. Rest of South America In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 217. Rest of South America In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 218. Asia Pacific In-Vitro Toxicity Testing, by Country USD Million (2022-2027)
  • Table 219. Asia Pacific In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 220. Asia Pacific In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 221. Asia Pacific In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 222. Asia Pacific In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 223. Asia Pacific In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 224. China In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 225. China In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 226. China In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 227. China In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 228. China In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 229. Japan In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 230. Japan In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 231. Japan In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 232. Japan In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 233. Japan In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 234. India In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 235. India In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 236. India In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 237. India In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 238. India In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 239. South Korea In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 240. South Korea In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 241. South Korea In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 242. South Korea In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 243. South Korea In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 244. Taiwan In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 245. Taiwan In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 246. Taiwan In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 247. Taiwan In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 248. Taiwan In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 249. Australia In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 250. Australia In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 251. Australia In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 252. Australia In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 253. Australia In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 254. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 255. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 256. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 257. Rest of Asia-Pacific In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 258. Rest of Asia-Pacific In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 259. Europe In-Vitro Toxicity Testing, by Country USD Million (2022-2027)
  • Table 260. Europe In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 261. Europe In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 262. Europe In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 263. Europe In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 264. Europe In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 265. Germany In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 266. Germany In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 267. Germany In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 268. Germany In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 269. Germany In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 270. France In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 271. France In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 272. France In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 273. France In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 274. France In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 275. Italy In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 276. Italy In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 277. Italy In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 278. Italy In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 279. Italy In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 280. United Kingdom In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 281. United Kingdom In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 282. United Kingdom In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 283. United Kingdom In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 284. United Kingdom In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 285. Netherlands In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 286. Netherlands In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 287. Netherlands In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 288. Netherlands In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 289. Netherlands In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 290. Rest of Europe In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 291. Rest of Europe In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 292. Rest of Europe In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 293. Rest of Europe In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 294. Rest of Europe In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 295. MEA In-Vitro Toxicity Testing, by Country USD Million (2022-2027)
  • Table 296. MEA In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 297. MEA In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 298. MEA In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 299. MEA In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 300. MEA In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 301. Middle East In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 302. Middle East In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 303. Middle East In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 304. Middle East In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 305. Middle East In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 306. Africa In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 307. Africa In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 308. Africa In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 309. Africa In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 310. Africa In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 311. North America In-Vitro Toxicity Testing, by Country USD Million (2022-2027)
  • Table 312. North America In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 313. North America In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 314. North America In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 315. North America In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 316. North America In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 317. United States In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 318. United States In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 319. United States In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 320. United States In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 321. United States In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 322. Canada In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 323. Canada In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 324. Canada In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 325. Canada In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 326. Canada In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 327. Mexico In-Vitro Toxicity Testing, by Type USD Million (2022-2027)
  • Table 328. Mexico In-Vitro Toxicity Testing, by Application USD Million (2022-2027)
  • Table 329. Mexico In-Vitro Toxicity Testing, by Technology USD Million (2022-2027)
  • Table 330. Mexico In-Vitro Toxicity Testing, by Methods USD Million (2022-2027)
  • Table 331. Mexico In-Vitro Toxicity Testing, by End User USD Million (2022-2027)
  • Table 332. In-Vitro Toxicity Testing: by Type(USD/Units)
  • Table 333. Research Programs/Design for This Report
  • Table 334. Key Data Information from Secondary Sources
  • Table 335. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global In-Vitro Toxicity Testing: by Type USD Million (2016-2021)
  • Figure 5. Global In-Vitro Toxicity Testing: by Application USD Million (2016-2021)
  • Figure 6. Global In-Vitro Toxicity Testing: by Technology USD Million (2016-2021)
  • Figure 7. Global In-Vitro Toxicity Testing: by Methods USD Million (2016-2021)
  • Figure 8. Global In-Vitro Toxicity Testing: by End User USD Million (2016-2021)
  • Figure 9. South America In-Vitro Toxicity Testing Share (%), by Country
  • Figure 10. Asia Pacific In-Vitro Toxicity Testing Share (%), by Country
  • Figure 11. Europe In-Vitro Toxicity Testing Share (%), by Country
  • Figure 12. MEA In-Vitro Toxicity Testing Share (%), by Country
  • Figure 13. North America In-Vitro Toxicity Testing Share (%), by Country
  • Figure 14. Global In-Vitro Toxicity Testing: by Type USD/Units (2016-2021)
  • Figure 15. Global In-Vitro Toxicity Testing share by Players 2021 (%)
  • Figure 16. Global In-Vitro Toxicity Testing share by Players (Top 3) 2021(%)
  • Figure 17. Global In-Vitro Toxicity Testing share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott (United States) Revenue: by Geography 2021
  • Figure 21. Covance (United States) Revenue, Net Income and Gross profit
  • Figure 22. Covance (United States) Revenue: by Geography 2021
  • Figure 23. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 24. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 25. Quest Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Quest Diagnostics, Inc. (United States) Revenue: by Geography 2021
  • Figure 27. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2021
  • Figure 29. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bio-Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 31. Catalent Pharma Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 32. Catalent Pharma Solutions (United States) Revenue: by Geography 2021
  • Figure 33. Cyprotex (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Cyprotex (Germany) Revenue: by Geography 2021
  • Figure 35. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 36. Agilent Technologies (United States) Revenue: by Geography 2021
  • Figure 37. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 38. Charles River Laboratories (United States) Revenue: by Geography 2021
  • Figure 39. Global In-Vitro Toxicity Testing: by Type USD Million (2022-2027)
  • Figure 40. Global In-Vitro Toxicity Testing: by Application USD Million (2022-2027)
  • Figure 41. Global In-Vitro Toxicity Testing: by Technology USD Million (2022-2027)
  • Figure 42. Global In-Vitro Toxicity Testing: by Methods USD Million (2022-2027)
  • Figure 43. Global In-Vitro Toxicity Testing: by End User USD Million (2022-2027)
  • Figure 44. South America In-Vitro Toxicity Testing Share (%), by Country
  • Figure 45. Asia Pacific In-Vitro Toxicity Testing Share (%), by Country
  • Figure 46. Europe In-Vitro Toxicity Testing Share (%), by Country
  • Figure 47. MEA In-Vitro Toxicity Testing Share (%), by Country
  • Figure 48. North America In-Vitro Toxicity Testing Share (%), by Country
  • Figure 49. Global In-Vitro Toxicity Testing: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Covance (United States)
  • GE Healthcare (United States)
  • Quest Diagnostics, Inc. (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Bio-Rad Laboratories (United States)
  • Catalent Pharma Solutions (United States)
  • Cyprotex (Germany)
  • Agilent Technologies (United States)
  • Charles River Laboratories (United States)
Additional players considered in the study are as follows:
Merck KgaA (Germany) , Eurofins Scientific, Inc. (Luxembourg)
Select User Access Type

Key Highlights of Report


Feb 2022 237 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global In-Vitro Toxicity Testing Market Quantitative research analysis
Global In-Vitro Toxicity Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The In-Vitro Toxicity Testing study can be customized to meet your requirements. The market size breakdown by type [Absorption, Toxic Substances and Dose], by end use application [Systemic Toxicology, Dermal Toxicity, Endorine Disruption, Occular Toxicity and Others].
The In-Vitro Toxicity Testing Market is gaining popularity and expected to see strong valuation by 2027.
According to AMA, the Global In-Vitro Toxicity Testing market is expected to see growth rate of 15.1%.

Know More About Global In-Vitro Toxicity Testing Market Report?

Have a Query? Click Here

Other Related Reports

Methyltestosterone Comprehensive Study by Type (Capsules, Tablets, Powder), Application (Medical {Delayed Puberty, Hypogonadism, Cryptorchidism, Erectile Dysfunction, Others}, Non-Medical), End Users...
$ 3500
Polycystic Ovary Syndrome (PCOS) Drugs Comprehensive Study by Application (Irregular periods, Excess androgen, Polycystic ovaries), Causes (Excess insulin, Low-grade inflammation, Heredity, Excess an...
$ 3350
Superdisintegrants Comprehensive Study by Type (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Application (Oncology, Neurology, Cardiology, Infectious Diseases), Types of Su...
$ 3650
Skin Antiseptic Products Comprehensive Study by Type (Solutions, Swab Sticks, Wipes), Application (Surgeries, Injections), Formulations (Alcohols, Iodine, Chlorhexidine, Octenidine, Others), Distribu...
$ 3450
Bio-pharmaceuticals Comprehensive Study by Type (Monoclonal Antibodies (moAb), Biotech Vaccines, Recombinant Human (RH) Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Interfe...
$ 3750
Tramadol HCL Comprehensive Study by Type (Intramuscular Injection, Oral, Rectal Administration), Application (Headache, Nausea, Somnolence, Dizziness, Constipation, Dry Mouth, Others (Sweating, Asthe...
$ 3750